JLE

L'Information Psychiatrique

MENU

La dépendance à la prégabaline : à propos d’un cas Volume 95, numéro 7, Août-Septembre 2019

  • [1] Baldwin D., Ajel Nowak R., Masdrakis V. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013;9:883-892.
  • [2] Verma V., Singh N., Singh Jaggi A. Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014;12:44-56.
  • [3] Yargic I., Ozdemiroglu F.A. Pregabalin abuse: a case report /Pregabalin kötüye kullanımı: Bir olgu sunumu. Klin Psikofarmakol. Bül Bull Clin Psychopharmacol. 2011;21:64-66.
  • [4] Bossard J.-B., Pont C., Dupouy J., Lapeyre-Mestre M., Jouanjus E. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. Clin Drug Investig. 2016;36:735-742.
  • [5] Blommel M.L., Blommel A.L. Pregabalin: An antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm. 2007;64:1475-1482.
  • [6] Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs. 2012;21:1243-1245.
  • [7] Delvaux M. Pharmacology and clinical experience with fedotozine. Expert Opin Investig Drugs. 2001;10:97-110.
  • [8] Cardenas D.D., Nieshoff E.C., Suda K., Goto S., Sanin L., Kaneko T. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology. 2013;80:533-539.
  • [9] Olaizola I., Ellger T., Young P., Bösebeck F., Evers S., Kellinghaus C. Pregabalin-associated acute psychosis and epileptiform EEG-changes. Seizure. 2006;15:208-210.
  • [10] Pedroso J.L., Nakama G.Y., Carneiro Filho M., Barsottini O.G. Delirium, psychosis, and visual hallucinations induced by pregabalin. Arq Neuropsiquiatr. 2012;70:960-961.
  • [11] Schifano F., D’Offizi S., Piccione M., Corazza O., Deluca P., Davey Z. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118-122.
  • [12] Pregabalin og misbrukspotensial [Internet]. Tidsskrift for Den norske legeforening. https://tidsskriftet.no/2009/01/legemidler-i-praksis/pregabalin-og-misbrukspotensial.(consulté le 5 mars 2019).
  • [13] Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials [Internet]. Centre for Reviews and Dissemination (UK), 2011. https://www.ncbi.nlm.nih.gov/books/NBK81430/consulté le 10 juill 2017.
  • [14] Schwan S., Sundström A., Stjernberg E., Hallberg E., Hallberg P. A signal for an abuse liability for pregabalin—results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947-953.
  • [15] Arnold L.M., Russell I.J., Diri E.W., Duan W.R., Young J.P., Sharma U. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain Off J Am Pain Soc. 2008;9:792-805.
  • [16] Arnold L.M., Arsenault P., Huffman C., Patrick J.L., Messig M., Chew M.L. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30:2069-2083.
  • [17] Lang N., Sueske E., Hasan A., Paulus W., Tergau F. Pregabalin exerts oppositional effects on different inhibitory circuits in human motor cortex: a double-blind, placebo-controlled transcranial magnetic stimulation study. Epilepsia. 2006;47:813-819.
  • [18] Jouanjus E., Coutens B., Mouledous L., Manta S., Rampon C., Roussin A. Le système dopaminergique est-il impliqué dans le potentiel d’abus de la prégabaline ? Thérapie. 2018;73:563-564.
  • [19] Bockbrader H.N., Wesche D., Miller R., Chapel S., Janiczek N., Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661-669.
  • [20] Bockbrader H.N., Radulovic L.L., Posvar E.L., Strand J.C., Alvey C.W., Busch J.A. Clinical Pharmacokinetics of Pregabalin in Healthy Volunteers. J Clin Pharmacol. 2010;50:941-950.
  • [21] Evoy K.E., Morrison M.D., Saklad S.R. Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 2017;77:403-426.
  • [22] Chew M.L., Alvey C.W., Plotka A., Pitman V.W., Alebic-Kolbah T., Scavone J.M. Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. Clin Drug Investig. 2014;34:627-637.
  • [23] Grosshans M., Lemenager T., Vollmert C., Kaemmerer N., Schreiner R., Mutschler J. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021-2025.
  • [24] Wilens T., Zulauf C., Ryland D., Carrellas N., Catalina-Wellington I. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2014;24:173-177.